Quality Risk Management
ICH Q9(R1) Quality Risk Management Advisory
ICH Q9(R1) sets the standard for how pharmaceutical organisations identify, assess, and manage risk across their quality systems. Vitalane helps sponsors and manufacturers assess their current practices against the revised standard and build risk management frameworks that regulators expect to see.
Why ICH Q9(R1) Requires Active Attention
The revised standard clarifies expectations that were previously applied inconsistently. Organisations that have not assessed their risk management practices against Q9(R1) are likely to have gaps regulators will find.
Q9(R1) clarifies expectations that were previously ambiguous
The revised standard addresses subjectivity, formality, and documentation in risk assessments — areas where many organisations were applying Q9 inconsistently. Regulators are now applying Q9(R1) expectations in inspections.
Risk management underpins your entire quality system
ICH Q9(R1) is referenced throughout ICH Q10 and is the basis for risk-based approaches to supplier qualification, change control, validation, and CAPA. A weak risk management framework creates systemic gaps across the quality system.
Proportionate, practical implementation
Vitalane's approach to Q9(R1) advisory is practical — not theoretical. Risk management frameworks are designed to be proportionate to the organisation's size, complexity, and risk profile, and to integrate with existing quality systems rather than replace them.
Delivered by Bright Gnanaselvam directly
Every Q9(R1) engagement is conducted by Bright — not delegated to a junior consultant. Clients work directly with the practitioner from gap assessment through to implementation support.
What the Engagement Covers
Scope is agreed based on your organisation's current risk management maturity, quality system structure, and regulatory exposure. Engagements can cover the full Q9(R1) standard or focus on specific applications.
Conducted by Bright Gnanaselvam — MSc Pharmaceutical Sciences, MRSC — directly.
- Gap assessment of current risk management practices against ICH Q9(R1)
- Risk management framework design or redesign
- Risk assessment templates (FMEA, HACCP, risk ranking and filtering)
- Integration of Q9(R1) into change control, CAPA, and deviation processes
- Risk-based supplier and CMO qualification programme design
- Training and guidance for quality teams on Q9(R1) application
- Risk review programme design for ongoing risk management
- Advisory support through implementation
Common Questions
What changed in ICH Q9(R1) compared to the original Q9?
ICH Q9(R1) clarifies the role of subjectivity in risk assessments and introduces stronger expectations for formality and documentation in risk management activities. It emphasises that risk management should be proportionate to the level of risk and that risk review should be an ongoing activity — not a one-time exercise. Organisations that applied Q9 informally or inconsistently will likely have gaps against the revised standard.
Where does ICH Q9(R1) apply in pharmaceutical manufacturing?
ICH Q9(R1) applies across the pharmaceutical quality system — including manufacturing process risk assessments, supplier and CMO qualification, change control, deviation and CAPA management, validation and qualification activities, and supply chain risk management. It is also referenced in ICH Q10 as a foundational element of the Pharmaceutical Quality System.
How does Q9(R1) relate to supplier and CMO oversight?
ICH Q9(R1) provides the risk management framework that underpins supplier qualification and CMO oversight programmes. A risk-based approach to supplier auditing — determining audit frequency, scope, and depth based on assessed risk — is an expectation regulators apply when reviewing sponsor quality systems. Q9(R1) advisory from Vitalane can help sponsors design or improve their risk-based supplier oversight programmes.
Assess Your Q9(R1) Readiness
Book a short call with Bright to discuss your current risk management practices and where Q9(R1) is most likely to create gaps.